Towards an optimized and efficient organization in Medical Biology

The LNS Medical Biology Department performs a great array of over 1000 different tests spanning various specialties, including biochemistry, hormonology, medical toxicology, and allergology. Interactions with a wide range of stakeholders require optimal responsiveness and a robust structure to support this diversity. That is why, a new organization was proposed to and approved by the LNS Board of Directors in 2023. 

With the constant expansion of the test menu, better organization is essential for improved decision-making and increased efficiency.

In order to enable the department to keep pace with its evolution, marked by the ongoing development of separative methods (UPLC, LC-MS/MS, GC-MS) and a growing demand for medical toxicology, the department has been divided into two services:

• Newborn Screening and Inborn Errors of Metabolism (NBSIEM) Service: Accounting for 40% of the department’s analyses, this service is responsible for the national newborn screening program for all of Luxembourg.
• Pharmacology and Hormonology (PH) Service: Representing 60% of the analyses, it is responsible for Luxembourg’s only medical toxicology service.

The Central Reception, operating transversally for medical services, remains under the department’s responsibility.

Modernized and balanced management

The creation of services within the department strengthens the management structure, reducing the risk associated with reliance on the department head. Dr Patricia Borde declares: “This new structure also provides medical biologists with opportunities to develop their leadership skills and acknowledges their daily efforts in managing the entire workflow—from the pre-analytical phase to results and coordination of activities.”

Team reinforcement and continuous development

By adopting this new organizational structure, the Medical Biology Department is preparing to meet future challenges and maintain its leadership position in the field. The plan also includes reinforcing the team in 2024 with the addition of a scientist to support the expansion of newborn screening. This new team member will play a crucial role in developing numerous innovative projects.